TY - JOUR
T1 - Clinical features in salivary gland lymphoepithelial carcinoma in 10 patients
T2 - Case series and literature review
AU - Chou, Chiung Tung
AU - Ou, Chun Yen
AU - Lee, Wei Ting
AU - Hsu, Heng Jui
N1 - Funding Information:
This study was supported by the Department of Otolaryngology, National Cheng Kung University Hospital. The authors have no other funding, financial relationships.
Funding Information:
The authors thank the colleagues of the ENT Department at National Cheng Kung University Hospital who participated in the study. This manuscript was edited by Editage Academic Editing.
Publisher Copyright:
© 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.
PY - 2022/6
Y1 - 2022/6
N2 - Objective: Lymphoepithelial carcinoma (LEC) accounts for 0.4% of malignant tumors of the salivary gland and 0.8% of parotid gland malignancies. Over the past 50 years, less than 300 cases have been reported in the literature. The purpose of this study was to investigate the characteristics of salivary gland LEC. Methods: We retrospectively reviewed the medical records and analyzed clinical data obtained from 10 patients seen at our hospital between 2005 and 2020 with salivary gland LEC. Results: All patients presented with a self-palpable, non-tender, hard swelling, or lump near the jaw or infra-auricular region. Most cases (n = 8) were of solitary tumors, and enhancing patterns on computed tomography mainly were homogenous (n = 8). Interestingly, eight patients tested positive for the Epstein–Barr encoding region in in situ hybridization. Still, only three patients had detectable circulating Epstein–Barr virus (EBV) DNA, and one patient had detectable EBV IgA. All patients underwent complete tumor resection, followed by radiotherapy, and six also underwent chemotherapy. Nine patients became disease-free within 5 years, and one died due to disease 4 years after surgery. Conclusion: Although rare and considered to be a high-risk malignancy, LECs have favorable treatment outcomes. Circulating EBV DNA is still not considered a marker for preoperative assessment or postoperative treatment response. The role of EBV DNA requires further investigation. Level of Evidence: 4.
AB - Objective: Lymphoepithelial carcinoma (LEC) accounts for 0.4% of malignant tumors of the salivary gland and 0.8% of parotid gland malignancies. Over the past 50 years, less than 300 cases have been reported in the literature. The purpose of this study was to investigate the characteristics of salivary gland LEC. Methods: We retrospectively reviewed the medical records and analyzed clinical data obtained from 10 patients seen at our hospital between 2005 and 2020 with salivary gland LEC. Results: All patients presented with a self-palpable, non-tender, hard swelling, or lump near the jaw or infra-auricular region. Most cases (n = 8) were of solitary tumors, and enhancing patterns on computed tomography mainly were homogenous (n = 8). Interestingly, eight patients tested positive for the Epstein–Barr encoding region in in situ hybridization. Still, only three patients had detectable circulating Epstein–Barr virus (EBV) DNA, and one patient had detectable EBV IgA. All patients underwent complete tumor resection, followed by radiotherapy, and six also underwent chemotherapy. Nine patients became disease-free within 5 years, and one died due to disease 4 years after surgery. Conclusion: Although rare and considered to be a high-risk malignancy, LECs have favorable treatment outcomes. Circulating EBV DNA is still not considered a marker for preoperative assessment or postoperative treatment response. The role of EBV DNA requires further investigation. Level of Evidence: 4.
UR - http://www.scopus.com/inward/record.url?scp=85129551221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129551221&partnerID=8YFLogxK
U2 - 10.1002/lio2.811
DO - 10.1002/lio2.811
M3 - Article
AN - SCOPUS:85129551221
SN - 2378-8039
VL - 7
SP - 779
EP - 784
JO - Laryngoscope investigative otolaryngology
JF - Laryngoscope investigative otolaryngology
IS - 3
ER -